STAT+: Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Why it matters: Neurocrine Biosciences gains the exclusive approved treatment for hyperphagia in Prader-Willi syndrome patients.
- Neurocrine Biosciences announced its intention to purchase Soleno Therapeutics for $2.9 billion.
- Soleno Therapeutics will be acquired at $53 per share, representing a 34% premium over its previous closing price.
- Vykat, Soleno's drug, was approved in March 2025 as the only treatment for hyperphagia, the relentless hunger associated with Prader-Willi syndrome.
Neurocrine Biosciences is set to acquire Soleno Therapeutics for $2.9 billion, a move driven by Soleno's recently approved drug, Vykat, which addresses hyperphagia in Prader-Willi syndrome patients. This acquisition provides Neurocrine with the sole approved treatment for a defining and challenging symptom of the rare genetic disease.
